Toward Noninvasive Genomic Screening of Lung Cancer Patients

[1] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004

[2] Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2653 - 2659

[3] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) : 20932 - 20937

[4] A blood-based test for epidermal growth factor receptor mutations in lung cancer -: Commentary [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3875 - 3877

[5] Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer:: The ONCOBELL trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) : 2248 - 2255

[6] Detection of epidermal growth factor receptor variations by partially denaturing HPLC [J]. CLINICAL CHEMISTRY, 2007, 53 (01) : 62 - 70

[7] Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer [J]. CANCER, 2006, 107 (12) : 2858 - 2865

[8] DOUILLARD J, 2008, J CLIN ONCOL, V26, pS424

[9] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043

[10] Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants [J]. PLOS MEDICINE, 2005, 2 (11) : 1167 - 1176

[1] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004

[2] Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2653 - 2659

[3] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) : 20932 - 20937

[4] A blood-based test for epidermal growth factor receptor mutations in lung cancer -: Commentary [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3875 - 3877

[5] Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer:: The ONCOBELL trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) : 2248 - 2255

[6] Detection of epidermal growth factor receptor variations by partially denaturing HPLC [J]. CLINICAL CHEMISTRY, 2007, 53 (01) : 62 - 70

[7] Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer [J]. CANCER, 2006, 107 (12) : 2858 - 2865

[8] DOUILLARD J, 2008, J CLIN ONCOL, V26, pS424

[9] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043

[10] Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants [J]. PLOS MEDICINE, 2005, 2 (11) : 1167 - 1176